Navigation Links
Harnessing anticancer drugs for the future fight against influenza
Date:9/5/2012

Medical Systems Virology group at the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, together with its national and international collaborators, developed a new cell screening method that can be used to identify potential anti-influenza drugs. The researchers were able to identify two novel compounds with anti-influenza activity, obatoclax and gemcitabine and prove the efficacy of a previously known drug saliphenylhalamide.

The study was recently accepted for publication in the Journal of Biological Chemistry and is now available online.

Influenza viruses cause significant human morbidity and mortality. To treat the infections, different virus-directed drugs have been developed. However, the currently available drugs are targeting viral proteins and due to a high mutation rate the influenza viruses quickly develop resistance to them. For that reason, next-generation antiviral drugs should be directed towards the host functions. The results of this study provide a foundation for development of next-generation antiviral drugs. Furthermore, these identified compounds can be used as chemical tools when studying the molecular mechanisms of virus-host interactions.

"An interesting aspect of this study is that the antiviral effects of obatoclax, saliphenylhalamide and gemcitabine, which all are either investigational or approved anticancer agents, are achieved at much lower concentrations than that needed to mediate cancer cell death" said the group leader Denis Kainov.

However, further research is still needed before these drugs can be clinically tested and applied in influenza infections.

This research project is a good example of repurposing of drugs, i.e. finding new applications for existing drugs and thus saving money and time on drug development.

"We anticipate that these types of drugs could in the future reinforce the therapeutic arsenal and address the needs of the society to control influenza outbreaks", said Olli Kallioniemi, the Director of FIMM.


'/>"/>
Contact: Dr. Laura Kakkola
laura.kakkola@fimm.fi
358-503-112-552
University of Helsinki
Source:Eurekalert  

Related biology news :

1. Harnessing the Materials Genome Conference
2. A new vision for harnessing data about life on Earth
3. High levels of TRAIL protein in breast milk might contribute to anticancer activity
4. Chemicals today, drugs tomorrow: U-Ms new Center for Drug Discovery
5. Target for potent first-strike influenza drugs identified
6. 3-D motion of cold virus offers hope for improved drugs using Australias fastest supercomputer
7. Single protein promotes resistance to widely used anti-estrogen drugs
8. Efforts to develop new drugs that hopefully will never be used
9. Arsenic for better drugs and cleaner crops
10. MIT-designed cooler preserves tuberculosis drugs, records doses
11. La Jolla Institute discovery could lead to new way to screen drugs for adverse reactions
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Harnessing anticancer drugs for the future fight against influenza
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... today announces publication of a United States multicenter, prospective clinical study that ... disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial and ...
(Date:10/11/2017)... ... 2017 , ... At its national board meeting in North ... the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology and ... ARCS Alumni Hall of Fame . ASTER Labs is a technology development ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
Breaking Biology Technology: